StockAnalyzer

Financial Analysis

DashboardSectorsComparablesScreenerUniverseMicrocapsAI 2nd OrderTheme MapEnergy & MaterialsMacroWatchlistCompareMi CarteraPortfolio

Recent

v0.1
6029.T$200.00-3.35%
Fair $200.00+0.0%

6029.T

Artra Group Corporation

Healthcare / Medical Care FacilitiesTokyo

$200.00

-7.00 (-3.35%)

Fairly Valued+0.0%Fair Value $200.00Fund rank 24/100 · Data gapFallback financials|
SA 57/C
F-Score: 6/9
Declining Revenue

FCF base 3Y

n/d

n/d CAGR · yield n/d

FCF base 5Y

n/d

n/d base · n/d expected

Precio de entrada

n/d

MOS 34% · confianza 17%

FCF escenarios

weak_data · normalized FCF $122.4M · quality 39.7/100

Data gap 24/100
Bear 5Yn/dn/d
Base 5Yn/dn/d
Bull 5Yn/dn/d
Return 0/100Downside 20/100Model quality 7/100Data QA 20/100

Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.

Quality + valuation scorecard

SA Score

57/100

C

Piotroski

6/9

balance/quality

Valuation

50/100

+0.0% upside

5Y CAGR

+0.0%

50/100

Data QA

16/100

SEC 0%

Latest source: unknownPeriods: 4Warnings: 1unknown: 4
No SEC-backed annual rows; valuation uses fallback financial data. Insufficient audited annual history (<3 SEC-backed years); composite fair value and forward targets are disabled until manually verified. Revenue has declined for 3 consecutive years
Thesis & Journal · 6029.TLocal privado en este navegador · Artra Group Corporation
Plantilla tipo buy-side: tesis, bull/base/bear, catalizadores, riesgos, kill criteria y fecha de revisión. Esto no gasta GPT-5.5; luego lo usamos como contexto del memo.

Sin guardar todavía.

Market Cap

$2.1B

P/E

7.9x

↓

EV/EBITDA

5.5x

↓

ROE

15.2%

↑

Gross Margin

34.3%

↓

Debt/Equity

0.62

↑
52-Week Range$200
$134$352

TradingView lightweight chart

6029.T price, volumen y niveles de valoración

Último $202.00Periodo -40.2%
Fair value: $200.00

Price & Ratios

Absolute Values (Left Axis)

Ratios / Percentages (Right Axis)

Financial statement dashboard

Crecimiento, márgenes y provenance

2022–2025 · 3 años de histórico normalizado

Revenue CAGR

-5.6%

FCF CAGR

—

FCF margin

5.0%

FCF / Net income

0.76x

Latest source

Provider fallback

Margin decomposition

Último año: revenue $3.93B · net income $258.3M · FCF $197.0M

2022-FY → 2025-FY

Gross margin

34.3%+0.6% pts

Operating margin

3.6%+3.5% pts

Net margin

6.6%+6.5% pts

FCF margin

5.0%+11.2% pts
MetricTTM
2025
2024
2023
2022
Income Statement
Revenue$3.93B$3.93B$4.23B$4.50B$4.67B
Net Income$258.3M$258.3M$-36.7M$54.0M$2.1M
EBITDA$360.5M$360.5M$146.8M$228.1M$190.6M
EPS——-3.595.430.22
Gross Margin34.3%34.3%31.5%32.5%33.7%
Operating Margin3.6%3.6%0.1%1.1%0.1%
Net Margin6.6%6.6%-0.9%1.2%0.0%
Balance Sheet
Debt/Equity0.620.620.891.061.46
Current Ratio1.311.31———
Cash Flow
Free Cash Flow$197.0M$197.0M$122.4M$94.2M$-288.9M
Returns
ROE15.2%15.2%-2.6%3.7%0.2%
Valuation
P/E7.957.95—34.99822.73
EV/EBITDA5.485.4810.9610.0112.81
P/B1.211.210.961.301.35
Growth & Yield
Revenue Growth-7.3%-7.3%-5.9%-3.7%—
EPS Growth——-166.1%2368.2%—

Revenue, Net Income & Free Cash Flow ($B)

Margins (%)

Returns (%)

Leverage & Liquidity

Reverse DCF · market-implied EPS growthterminal P/E 15.0x · COE 10.0%
Reverse DCF requires positive EPS; loss-making or zero-EPS companies cannot produce a clean EPS hurdle.

Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.

Return attribution · 1Y approxreconcilia total +18.8%

Total return

+18.8%

Start / end P/E

n/dx → n/dx

EPS bridge

-3.59 → n/d

Residual

+18.8%

EPS growthn/d
Multiple reratingn/d
Dividend+0.0%
Residual / FX / buybacks / cross-term+18.8%

EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.

Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.